All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches

CEConversations

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis) in MF. These clinicians and their interdisciplinary collaborative care team need a deeper understanding of JAKis in MF, guideline-recommended risk-stratification algorithms, molecular indicators of disease prognosis, clinical features of MF, symptom burden, the impact of adverse events on treatment adherence, and health disparities in MF.

In this CE Concepts recorded Grand Rounds, expert faculty will discuss assessing patients for MF therapy, integrating current and emerging data on JAKis in MF, developing individualized strategies to reduce treatment toxicity and enhance treatment adherence, and evaluating health disparities in MF. The faculty will also provide insight through case examples.
Learn More at: | https://www.ceconcepts.com/activity/all-hands-on-deck-utilizing-jak-inhibitors-in-myelofibrosis-care-evidence-timing-and-strategic-approaches/